FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 707 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost... December 13, 2019 Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A October 3, 2023 Olivia Newton-John Puts On Iconic ‘Grease’ Costume And Talks About Cancer... October 3, 2019 Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October October 14, 2024 Load more HOT NEWS Holidays, Traditions and Grief 10 Tips for Healthy Eating After Cancer Treatment Rare Disease Day: Raising Awareness for Rare Cancers Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for...
